NEW YORK and TORONTO and HERZLIYA, Israel, Sept. 01, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (the “Company”) is pleased to announce...
TORONTO, July 19, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (TSX: INCR.U, TASE: INCR)(dba Canndoc)(the “Company”) is pleased to announce that further to its confidential filing with the U.S...
TORONTO and HERZLIYA, Israel, July 10, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (TSX: INCR.U, TASE: INCR)(dba Canndoc)(the “Company”) is pleased to announce that further to its confidential...
Acquisition of one of the leading active, IMCA approved trade houses in Israel expanding InterCure's sales channel, distribution, delivery and storage capacity. As part of the acquisition, two...
TORONTO and HERZLIYA, Israel, May 17, 2021 (GLOBE NEWSWIRE) -- InterCure Ltd. (TSX: INCR:U, TASE: INCR)(dba Canndoc)("Intercure" or the the “Company”) today reported financial results for the...
Revenues expected to reach a record NIS 33 million (over CAD$12 million) Revenue growth of 8 times YoY and increased more than 22% sequentially Continued increase in operating profit, EBITDA and...
This is the first branch under the “LEMONNADE” brand (from the Cookies family) outside of North America LEMONNADE Jerusalem is another flagship branch in InterCure's leading, medical cannabis...
This is the first branch under the “LEMONNADE” brand (from the Cookies family) outside of North America LEMONNADE Jerusalem is another flagship branch in InterCure's leading, medical cannabis...
Subversive Acquisition LP Has Met All Conditions of Closing and Expects to Close on or Before Friday April 23, 2021 SPAC Restricted Voting Units Currently Trade on the TSX Under the Symbol “SVX.U”...
Incara Begins Transition to Clinical Development Phase of Lead Molecule For ALS and Ushers in New Board of Directors to Manage Transition NEW YORK, April 30 /PRNewswire-FirstCall/ -- Goodnow...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales